Document Detail

Zoledronic acid: a review of its use in the treatment of osteoporosis.
MedLine Citation:
PMID:  18947264     Owner:  NLM     Status:  MEDLINE    
Zoledronic acid (Aclasta; Reclast), a third-generation nitrogen-containing bisphosphonate, is the first once-yearly treatment to have been approved for use in patients with postmenopausal osteoporosis or at high risk of fracture. Intravenous zoledronic acid 5 mg once yearly is effective in reducing the risk of several types of fracture in patients with postmenopausal osteoporosis or recent low-trauma hip fracture. Moreover, improvements in bone mineral density (BMD) and reductions in markers of bone turnover are also generally observed. Zoledronic acid is generally well tolerated. Additional comparative data are required to definitively position zoledronic acid with respect to other agents. In the meantime, intravenous zoledronic acid 5 mg once yearly is a convenient and effective treatment option that may have an advantage over some other agents, for which adherence to treatment regimens is a recognized problem.
Emma D Deeks; Caroline M Perry
Related Documents :
2105864 - Valproic acid-associated pancreatitis: report of three cases and a brief review.
8427944 - Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of val...
14595654 - Valproic acid increases smn levels in spinal muscular atrophy patient cells.
23411274 - Malolactic fermentation of wines with immobilised lactic acid bacteria - influence of c...
23140684 - Amino acid uptake by wild and commercial yeasts in single fermentations and co-fermenta...
11775354 - Structural determination of subsidiary colors in commercial food green no. 3 (fast gree...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs & aging     Volume:  25     ISSN:  1170-229X     ISO Abbreviation:  Drugs Aging     Publication Date:  2008  
Date Detail:
Created Date:  2008-10-24     Completed Date:  2009-01-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9102074     Medline TA:  Drugs Aging     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  963-86     Citation Subset:  IM    
Wolters Kluwer Health, Adis, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Density / drug effects
Bone Density Conservation Agents / administration & dosage,  adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Diphosphonates / administration & dosage,  adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Fractures, Bone / epidemiology,  prevention & control
Hip Fractures / epidemiology,  prevention & control
Imidazoles / administration & dosage,  adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Osteoporosis / drug therapy*
Osteoporosis, Postmenopausal / drug therapy
Reg. No./Substance:
0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an o...
Next Document:  Use of flowable composites for orthodontic bracket bonding.